Macleods is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $24.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Macleods' stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | FDA-approved 16 Oct 2024 | $7.7B |
| Xarelto | Bayer / Johnson & Johnson | Generic | 2025 | FDA-approved 14 May 2025 | ≈$5.3B |
| Farxiga | AstraZeneca | Generic | 2026 | FDA-approved 6 Apr 2026 | $8.4B |
| Descovy | Gilead | Generic | 2031 | FDA-approved 7 Apr 2026; settled 2022 | $2.8B |
Company facts: Macleods. Each drug page lists sources for these entries. Brand sales show the size of the market, not Macleods' share of it.
Macleods has FDA approval for Entresto, Farxiga, Descovy and Xarelto, with no US launch confirmed. It has settled with the brand owner over 1 drug. Of the 70 makers we follow, 21 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.